An observational study in Hypogonadism, Male, Endocrine Disease and Hypertension, sponsored by Hacettepe University. Recruiting at 2 sites in Turkey (Türkiye). Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Hacettepe University · Observational
This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.
Hypogonadism is a chronic endocrine condition characterized by subnormal serum testosterone levels. Unlike other chronic metabolic conditions, hypogonadism directly threatens core attributes of male gender identity, including sexual function, physical capacity, and reproductive potential. While biological manifestations and medical management are well documented, the psychosocial dimensions of hypogonadism, specifically anticipated stigma and illness identity, remain insufficiently explored in clinical research.
Anticipated stigma involves cognitive expectations of negative reactions, judgment, or discrimination from interpersonal, occupational, and healthcare environments. In conditions where illness poses a direct threat to gender role identity, anticipated stigma may be heightened compared to non-identity-threatening chronic conditions such as diabetes or hypertension. Furthermore, the degree to which an individual integrates the diagnosis into their self-concept (illness identity) may interact with anticipated stigma to exacerbate health-related quality-of-life impairments.
This study systematically evaluates anticipated stigma and illness identity in men with hypogonadism in comparison to age-matched controls with other chronic endocrine conditions treated in the same clinical setting. The primary objective is to determine whether anticipated stigma levels differ significantly between these groups and to examine the predictive capacity of anticipated stigma and illness identity on disease-specific symptom burden and quality-of-life outcomes within the hypogonadism cohort.
75 studies on the registry are indexed under Eunuchism; 21 are open to participants now.
This study's planned enrollment of 90 is close to the median of 100 across 17 observational studies indexed under Eunuchism.
Browse Eunuchism studies →Hacettepe University is the lead sponsor of 1,007 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Male patients aged 18 years and older who are routinely followed up at the endocrinology outpatient clinic of Malatya Training and Research Hospital. The population comprises two distinct subgroups: men with a biochemically confirmed diagnosis of hypogonadism and age-matched men diagnosed with other chronic endocrine or metabolic conditions (diabetes mellitus, hypertension, or hypothyroidism) without hypogonadism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cases:
Controls:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male patients aged 18 years or older with biochemically confirmed hypogonadism (total testosterone \< 300 ng/dL with at least one clinical symptom) undergoing regular follow-up in the endocrinology clinic.
Male patients aged 18 years or older diagnosed with diabetes mellitus, hypertension, or hypothyroidism without hypogonadism (total testosterone ≥ 300 ng/dL), matched by age (±5 years) to the case group and under regular follow-up in the same endocrinology clinic.
Chronic Illness Anticipated Stigma Scale (CIASS) Score
Measures anticipated stigma across three subscales (friends/family, work, healthcare workers) on a 5-point Likert scale.
Time frame: Baseline (Single session, day 1)
Brief Illness Perception Questionnaire (Brief IPQ) Score
Assesses cognitive and emotional representations of illness. Higher total scores indicate a more threatening illness perception.
Time frame: Baseline (Single session, day 1)
Aging Males' Symptoms (AMS) Scale Score
Evaluates the severity of symptoms related to aging/hypogonadism across somatic, psychological, and sexual domains.
Time frame: Baseline (Single session, day 1)
Hospital Anxiety and Depression Scale (HADS) Score
Measures anxiety and depression symptom severity via 14 items (7 anxiety, 7 depression).
Time frame: Baseline (Single session, day 1)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.